Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Genomics for Drug Discovery, Validation and Clinical Development with AstraZeneca, Pf

    In just two weeks, Cambridge Healthtech Institute's NGS for Drugs, Patients and Clinical Trials will feature a series of opening discussions focused on the utilization of genomic data for decision making during drug development, including steps for discerning and validating targets, model selection, biomarker development, patient stratification and CAP/CLIA-certified operations.

    Join leaders from Pfizer, AstraZeneca, Sanofi, Gilead, Genedata and Washington University, as they share their first-hand experiences using genomic information for data driven decision making.

    Featured Session Presentations:

    Profiling and NGS in Cancer: Challenges and Applications to Targets, Models, and Resistance
    Paul Rejto, Ph.D., Director, Computational Biology, Oncology Research Unit, Pfizer, Inc.

    Impact of Next-Generation Sequencing on Oncology Drug Discovery and Early Clinical Development
    Oleg Iartchouk, Ph.D., Lead Scientist and Lab Head, Applied Genomics, Translational and Experimental Medicine, Sanofi

    Uncovering Genetic Interactions in Tumor Cell Lines: A Workflow-Based Approach for NGS Analysis
    Benjamin J. Adamczyk, Ph.D., Scientific Account Manager, Genedata USA, Inc.

    Devising Methods for Intuitively Handling Huge Data Sets to Simplify Biomarker Discovery
    Dongliang Ge, Ph.D., Director, Bioinformatics, Gilead Sciences, Inc.

    Stratification of Clinical Trial Subjects Using Biomarkers Developed by Next-Generation Sequencing
    Brian Dougherty, Ph.D., Lead, Translational Genomics, Oncology, AstraZeneca

    From Theory to Practice: Our First Thousand Samples
    Seth D. Crosby, M.D., Director, Alliances and Partnerships, Department of Genetics, Washington University School of Medicine

    NGS for Drugs, Patients and Clinical Trials
    March 21-22, 2013
    Hilton San Diego Resort
    Learn more at healthtech.com/ngs-drug-development

Latest Articles

Collapse

  • seqadmin
    Strategies for Sequencing Challenging Samples
    by seqadmin


    Despite advancements in sequencing platforms and related sample preparation technologies, certain sample types continue to present significant challenges that can compromise sequencing results. Pedro Echave, Senior Manager of the Global Business Segment at Revvity, explained that the success of a sequencing experiment ultimately depends on the amount and integrity of the nucleic acid template (RNA or DNA) obtained from a sample. “The better the quality of the nucleic acid isolated...
    03-22-2024, 06:39 AM
  • seqadmin
    Techniques and Challenges in Conservation Genomics
    by seqadmin



    The field of conservation genomics centers on applying genomics technologies in support of conservation efforts and the preservation of biodiversity. This article features interviews with two researchers who showcase their innovative work and highlight the current state and future of conservation genomics.

    Avian Conservation
    Matthew DeSaix, a recent doctoral graduate from Kristen Ruegg’s lab at The University of Colorado, shared that most of his research...
    03-08-2024, 10:41 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by seqadmin, Yesterday, 06:37 PM
0 responses
10 views
0 likes
Last Post seqadmin  
Started by seqadmin, Yesterday, 06:07 PM
0 responses
9 views
0 likes
Last Post seqadmin  
Started by seqadmin, 03-22-2024, 10:03 AM
0 responses
49 views
0 likes
Last Post seqadmin  
Started by seqadmin, 03-21-2024, 07:32 AM
0 responses
67 views
0 likes
Last Post seqadmin  
Working...
X